🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 166 of 857 · Phase 3 first, then by program name

  1. SPD489 low dose range (40mg, 80mg, and 100mg)

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

  2. SPD503 (1 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  3. SPD503 (Guanfacine hydrochloride)

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  4. SPD503 (Guanfacine hydrochloride) (2 mg)

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    1 trial

  5. SPD503-AM

    Takeda

    ADHD

    phase 3 small molecule completed

    1 trial

  6. SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM

    Ars Pharmaceuticals Irl Limited

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule completed

    1 trial

  7. SPINRAZA 28 mg, SPINRAZA 50 mg

    Biogen

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  8. SPINRAZA 50 mg, SPINRAZA 28 mg

    Biogen

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  9. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule terminated

    2 trials

  10. SPN-810

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  11. SPN-810 (18 mg)

    SUPERNUS PHARMACEUTICALS, INC.

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    2 trials

  12. SPT-07A injection

    BRIGHT MINDS BIOSCIENCES INC.

    Stroke, Acute

    phase 3 small molecule active

    1 trial

  13. SR-A + Epratuzumab

    United Therapeutics Europe Ltd

    Acute Lymphoblastic Leukemia (ALL)

    phase 3 small molecule completed

    1 trial

  14. SR34006 (idraparinux sodium) Injection

    Sanofi Pasteur

    Pulmonary Embolism

    phase 3 small molecule completed

    1 trial

  15. SRP-4045

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    2 trials

  16. SRP-9003

    Sarepta Therapeutics

    Limb-girdle Muscular Dystrophy

    phase 3 mab active

    2 trials

  17. SRP-9005

    Sarepta Therapeutics

    Muscular Dystrophies, Limb-Girdle

    phase 3 mab terminated

    1 trial

  18. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. STAGE-12

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 3 other completed

    1 trial

  20. STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend)., STAMARIL® , poeder en oplosmiddel voor suspensie voor injectie in voorgevulde spuit. Gelekoortsvaccin (levend).

    The George Institute

    Yellow fever

    phase 3 small molecule active

    1 trial

  21. STELARA 90 mg solution for injection in pre-filled syringe, Guselkumab, STELARA 45 mg solution for injection, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  22. STELARA 90 mg solution for injection in pre-filled syringe, Solution for injection in pre-filled syringe without Ustekinumab 45, Solution for injection in pre-filled syringe without Ustekinumab 90, STELARA 45 mg solution for injection, JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  23. STK-001, STK-001

    Stoke Therapeutics

    Dravet syndrome

    phase 3 small molecule active

    1 trial

  24. SUBLOCADE

    Indivior Pty Ltd

    Opioid Use Disorder

    phase 3 small molecule terminated

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources